Genomic Vision Presented the Interim Results of Its Clinical Trial in Cervical Cancer Screening at the Eurogin Annual Congress
October 11 2017 - 11:47AM
Business Wire
Regulatory News:
Genomic Vision (FR0011799907 – GV) (Paris:GV), a company
specializing in the development of diagnostic tests for the early
detection of cancers and hereditary diseases, and in applications
for life sciences research laboratories, announces that it has
today presented the interim results of its clinical trial in HPV
(human papillomavirus) at the Eurogin 2017 (EUropean Research
Organisation on Genital Infection and Neoplasia) annual congress in
Amsterdam, the Netherlands.
The primary endpoint of the EXPL-HPV-002 study, initiated in
July 2016, is to evaluate the integration of the HPV virus as a
biomarker for diagnosing high-risk precancerous lesions requiring
an appropriate treatment. Promising preliminary results were
announced in May 2017 based on the interim analysis of 126 patients
positively tested for at least one of the 14 high-risk HPV. They
demonstrate that the integration of 14 high-risk human
papillomaviruses (HR-HPV) detected by molecular combing serves as a
relevant indicator of how severe the precancerous lesions are. To
date, 472 patients between 25 and 65 years old have been enrolled
in the study (including 164 patients with high-grade lesions and 31
with low-grade lesions) out of approximately 600 patients in total,
and the final analysis of the results is expected in early
2018.
The interim results were presented today at the Eurogin congress
during a session on molecular and biological markers by Dr.
Vladimír Dvořák, Head Physician at the Brno Centre for Outpatient
Gynecology and Primary Care in the Czech Republic and principal
investigator for the study: “The clinical results to date
emphasize the importance of molecular combing in improving the
detection of precancerous lesions of cervix. They naturally need to
be confirmed in a larger number of patients, as the final
statistical analysis requires 60 patients with low-grade lesions
and 60 with high-grade lesions. If the final results are positive,
molecular combing will become an additional efficient tool for a
more accurate evaluation of the lesions’ severity, and hence of the
risk of developing cervical cancer, thus enabling patients to
receive the optimal care.”
Anne Jacquet, Biomedical Research Director at Genomic Vision,
adds: “We are delighted with the substantial interest of the
scientific community in our interim results presented today at
Eurogin. It illustrates the need and importance of new diagnostic
approaches in the detection of cervical cancer. The presentation of
our results at the annual congress bringing together international
and multidisciplinary experts in HPV demonstrates that all the
advances allowing a predictive diagnostic of the appearance and
progression of the disease are highly awaited.”
ABOUT EUROGIN
Since 1994, the Eurogin annual congress has brought together
researchers and clinicians to raise the scientific community’s
awareness of diagnostic and prevention tools for genital infections
and neoplasia. It is a multidisciplinary international congress on
HPV attended by all scientific and industrial experts who share
their expertise and opinion to define what the priorities should be
with regards to the issue of HPV-induced cancer.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong technology allowing to identify
genetic abnormalities, GENOMIC VISION stimulates the R&D
productivity of the pharmaceutical companies, the leaders of the
diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 60 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of CAC® Mid & Small and
CAC® All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171011005870/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorUlysse
CommunicationPress RelationsBruno Arabian, +33 1 83 62 34
84barabian@ulysse-communication.comorNewCapInvestor
RelationsDušan Orešanský / Emmanuel Huynh+33 1 44 71 94
92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Sep 2023 to Sep 2024